|
1
|
Thun MJ, Henley SJ and Patrono C:
Nonsteroidal Anti-inflammatory drugs as anticancer agents:
Machanistic, pharmarcologic and clinical issues. J Natl Cancer
Inst. 94:252–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Claudius AK, Kankipati CS, Kilari RS,
Hassan S, Guest K, Russell ST, Perry CJ, Stark LA and Nicholl ID:
Identification of aspirin analogues that repress NF-κB signalling
and demonstrate anti-proliferative activity towards colorectal
cancer in vitro and in vivo. Ocol Rep. 32:1670–1680. 2014.
|
|
3
|
Ulrich CM, Bigler J and Potter JD:
Non-steroidal anti-inflammatory drugs for cancer prevention:
Promise, perils and pharmacogenetics. Nat Rev Cancer. 6:130–140.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Retsky M, Rogers R, Demicheli R, Hrushesky
WJ, Gukas I, Vaidya JS, Baum M, Forget P, Dekock M and Pachmann K:
NSAID analgesic ketorolac used perioperatively may suppress early
breast cancer relapse: Particular relevance to triple negative
subgroup. Breast Cancer Res Treat. 134:881–888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kreutz W: Diflunisal for the treatment of
cancer. German Patent WO/2005/016354. Filed August 18, 2004. Issued
February 24. 2005.
|
|
6
|
Bock JM, Menon SG, Goswami PC, Sinclair
LL, Bedford NS, Domann FE and Trask DK: Relative non-steriodal
anti-inflammatory drug (NSAID) antiproliferative activity is
mediated through p21-induced G1 arrest and E2F inhibition. Mol
Carcinog. 46:857–864. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang RA, Lu YY and Fan DM: Reasons for
cancer metastasis: A holistic perspective. Mol Clin Oncol.
3:1199–1202. 2014.
|
|
9
|
Plaks V, Koopman CD and Werb Z:
Circulating Tumor Cells. Science. 341:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaorav GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2002.
View Article : Google Scholar
|
|
12
|
Budd GT, Cristofanilli M, Ellis MJ,
Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV,
Terstappen LW and Hayes DF: Circulating tumor cells versus
imaging-predicting overall survival in metastatic breast cancer.
Clin Cancer Res. 12:6403–6409. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pachmann K, Camara O, Kavallaria A,
Krauspe S, Malarski N, Gajda M, Kroll T, Jörke C, Hammer U,
Altendorf-Hofmann A, et al: Monitoring the response of circulating
epithelial tumor cells to adjuvant chemotherapy in breast cancer
allows detection of patients at risk of early relapse. J Clin
Oncol. 26:1208–1215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pachmann K, Dengler R, Lobodasch K,
Fröhlich F, Kroll T, Rengsberger M, Schubert R and Pachmann U: An
increase in cell number at completion of therapy may develop as an
indicator of early relapse: Quantification of CETC for monitoring
of adjuvant therapy in breast cancer. J Cancer Res Clin Oncol.
134:59–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pachmann K, Camara O, Kavallis A,
Schneider U, Schünemann S and Höffken K: Quantification of the
response of circulating epithelial cells to neoadjuvant treatment
for breast cancer: A new tool for treatment monitoring. Breast
Cancer Res. 7:R975–R979. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reichle A and Vogt T: Systems Biology: A
Therapeutic Target for Tumor Therapy. Cancer Microenviron.
1:159–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rüdiger N, Stein EL, Schill E, Spitz G,
Rabenstein C, Stauch M, Rengsberger M, Runnebaum IB, Pachmann U and
Pachmann K: Chemosensitivity testing of circulating epithelial
tumor cells (cetc) in vitro: Correlation to in vivo sensitivity and
clinical outcome. J Cancer Ther. 4:597–605. 2013. View Article : Google Scholar
|
|
19
|
Camara O, Rengsberger M, Egbe A, Koch A,
Gajda M, Hammer U, Jörke C, Rabenstein C, Untch M and Pachmann K:
The relevance of circulating epithelial tumor cells (CETC) for
therapy monitoring during neoadjuvant (primary systemic)
chemotherapy in breast cancer. Ann Oncol. 18:1484–1492. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hekimian K, Meisezahl S, Trompelt K,
Rabenstein C and Pachmann K: Epithelial cell dissemination and
readhesion: Analysis of factors contributing to metastasis
formation in breast cancer. ISRN Oncol. 2012:6018102012.PubMed/NCBI
|
|
21
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Munson JM and Shieh AC: Interstitial fluid
flow in cancer: Implications for disease progression and treatment.
Cancer Manag Res. 6:317–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu JQ and Cristofanilli M: Circulating
tumor cells and PET. J Nucl Med. 52:1501–1504. 2011. View Article : Google Scholar : PubMed/NCBI
|
